scholarly journals Evaluation of G2350A Polymorphism of the Angiotensin-Converting Enzyme (ACE) Gene in Chronic Kidney Disease

2018 ◽  
Vol 15 (1) ◽  
pp. 151-155
Author(s):  
Narendra Mohan Verma ◽  
Arun Kumar Sah ◽  
Sanjeev Kumar Maurya
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Angiotensin Converting Enzyme ◽  
Uttar Pradesh ◽  
World Health ◽  
Individual Risk ◽  
Healthy Controls ◽  
Converting Enzyme ◽  
Ace Gene ◽  
And Control

Chronic kidney disease (CKD) becomes a major problem for world health. Numerous studies have documented that the polymorphisms in angiotensin-converting enzyme (ACE) gene may contribute to an individual risk for the loss of kidney function. The present study was undertaken to evaluate the possible relationship between ACE G2350A gene polymorphism and the risk of CKD in Uttar Pradesh population. A total of 379 (159 CKD patients and 220 healthy controls) subjects were recruited for this study. All subjects were genotyped for G2350A polymorphism by PCR-RFLP method. The significant differences were reported between CKD patients and control groups in height, BMI, WC, WH ratio, SBP, DBP, FBS, serum creatinine, eGFR, triglyceride, total cholesterol, HDL and LDL (p < 0.05); while there was no difference in weight, WC, HC and VLDL. The frequency of AA genotype and A-allele were significantly higher in healthy controls than to patients. Conclusively, this study showed that the G2350A polymorphism may not contribute to CKD risk. Further investigations are warranted in larger sample size to confirm our results.

scholarly journals Insertion / Deletion Polymorphism of Angiotensin Converting Enzyme Gene Does Not Contribute to Chronic Kidney Disease in Palestine

2018 ◽  
Vol 5 (4) ◽  
pp. 2160-2170
Author(s):  
Asmaa Mahmoud Abuaisha ◽  
Lamia Faisal Abou Marzoq ◽  
Mai Sufian Eljbour ◽  
Eman Saad Fayyad ◽  
Abeer Kamal Baraka ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Angiotensin Converting Enzyme ◽  
Gaza Strip ◽  
Study Groups ◽  
Repeat Sequence ◽  
P Value ◽  
Converting Enzyme ◽  
Retrospective Case ◽  
Ace Gene

Background: Chronic Kidney Disease (CKD) is progressive kidney damage in which the glomerular filtration rate (GFR) decreases by 15% of that performed by normal kidneys, with the result that the kidneys are no longer to function effectively and this condition is treated with either kidney transplantation or dialysis. Hemodialysis (HD) is a process in which the blood passes through a machine (dialyzer) to remove waste. Angiotensin Converting Enzyme (ACE) is one of the major components of the renin-angiotensin aldosterone system (RAAS) that is responsible for blood pressure regulation. Insertion/Deletion I/D polymorphism of a 287 bp Alu repeat sequence in introns 16 of the ACE gene results in three genotypes I/D, D/D and I/I. The aims of this study were to evaluate ACE genotypes and allele frequency among HD patients and control subjects and to examine the association between ACE genotypes with HD risk. Methods: A retrospective case-control study included 186 subjects, 86 HD patients and 100 healthy individuals as a control. EDTA whole blood samples were collected from all participants for DNA extraction, and the ACE gene polymorphism was analyzed by using the Polymerase Chain Reaction (PCR) technique. Additionally, all individuals were requested to complete the questionnaire. Results: The initial results demonstrated that the D/D genotype was the most common genotype in all subjects and the association between ACE genotypes with HD occurrence was not statistically significant in the Gaza Strip-Palestine. Furthermore, no statistically significant association was detected between the polymorphism and the study groups (p-value = 0.511).  

scholarly journals Does angiotensin-converting enzyme-1 (ACE-1) gene polymorphism lead to chronic kidney disease among hypertensive patients?

Renal Failure ◽  
2016 ◽  
Vol 38 (5) ◽  
pp. 765-769 ◽  
Author(s):  
Taposh Sarkar ◽  
Narinder Pal Singh ◽  
Premashish Kar ◽  
Syed Akhtar Husain ◽  
Seema Kapoor ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Gene Polymorphism ◽  
Angiotensin Converting Enzyme ◽  
Converting Enzyme ◽  
Hypertensive Patients

Possibilities of using fosinopril in treatment of patients with chronic kidney disease in combination with cardiovascular diseases and diabetes mellitus

2021 ◽  
pp. 17-25
Author(s):  
E. Yu. Ebzeeva ◽  
O. D. Ostroumova ◽  
S. V. Batyukina ◽  
N. A. Shatalova ◽  
N. M. Doldo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Kidney Disease ◽  
Cardiovascular Diseases ◽  
Kidney Disease ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitor ◽  
The Body ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Secondary Damage

Chronic kidney disease is one of the most common diseases in general medical practice, due to their secondary damage to the kidneys in arterial hypertension, chronic heart failure, and diabetes mellitus. The coexistence of hypertension and diabetes increases the likelihood of developing chronic kidney failure tenfold. In turn, chronic kidney disease is an important independent risk factor for the development of cardiovascular complications, including fatal ones, due to the direct relationship of the pathogenetic mechanisms of cardiorenal relationships. Approaches to the treatment of chronic kidney disease should be aimed both at preventing the risks of developing renal dysfunction, and at treating existing pathology. The multifactorial nature of the disease and the complex etiopathogenetic relationships determine the need to optimize existing approaches to the treatment of chronic kidney disease in multimorbidity patients with concomitance cardiovascular diseases and diabetes mellitus. This is also due to the fact that, unlike other target organs, compensation for background disease does not always prevent further deterioration of kidney function. According to the recommendations of the main scientific communities, in such cases, it is advisable to start therapy with the most effective angiotensin-converting enzyme inhibitors that combine nephro-and cardioprotective effects and have a dual route of elimination from the body, which is especially important in multimorbidity, the aim to prevent polypharmacy, reduce the risk of drug interactions and, consequently, side effects. This article reviews the literature data indicating the high efficacy and safety of the angiotensin converting enzyme inhibitor fosinopril in patients with chronic kidney disease in combination with cardiovascular diseases and diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document